Sector News

Sanofi and Lonza enter partnership to build biologics facility

February 28, 2017
Life sciences

The large-scale facility, to be built in Visp, Switzerland, will be established through a joint venture with an initial investment of around CHF 290 million (€270 million) shared equally between Sanofi and Lonza

The strategic partnership leverages Lonza’s expertise in large-scale mammalian cell culture facilities alongside Sanofi’s strength in developing and launching biologics based treatments to address patient needs. Lonza will construct the facility and will support the joint venture in its operation of the facility.

The initial phase of the facility will commence construction in 2017, pending necessary regulatory approvals, and is expected to be fully operational by 2020. Lonza has previously built and licensed three similar facilities in the US and Singapore.

Marc Funk is COO Pharma & Biotech at Lonza. He said: “We intend to address long-term market needs by establishing a state-of-the-art strategic biologics manufacturing platform.

“Approximately 60% of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology,” said Philippe Luscan, Executive Vice President, Global Industrial Affairs at Sanofi.

“Lonza is a highly experienced partner in this field and the capabilities this joint venture will create are critical to meeting our patients’ needs for these important therapies.”

The partnership provides both Sanofi and Lonza with substantial flexibility:

  • Each party will share the available capacity in line with their equity shareholding in the joint venture
  • Sanofi will have additional access to bio-manufacturing capacity
  • Lonza will be free to market their share of capacity and will also market unused Sanofi capacity

The strategic partnership enables Sanofi to react quickly to fluctuations in demand in a short timeframe, reinforcing their capability to launch high-quality, next generation biologic medicines and ensure consistent access for patients.

It also provides Lonza with the capacity to respond to growing manufacturing demands for large-scale mammalian cell culture based therapeutic proteins. By adding flexibility in this way, it is hoped this model will optimise biologics production capacity across the whole industry.

Source: Manufacturing Chemist

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach